从行业来看，高投入、高风险、长周期是创新药研发的典型特征，稳定且可预期的专利保护环境，是支撑创新持续投入的 重要基础，也是维护公平竞争秩序、为创新药研发成果提供必要的制度保障。 进一步资料显示，诉前行为保全是知识产权案件中的重要程序性制度安排，在法院对权利基础及紧急性进行初步审查后， 可依法采取临时措施，以避免权利人在案件审理期间遭受难以弥补的损害。 耐赋康于2023年11月在中国获批上市，是目前全球首个且唯一用于IgA肾病对因治疗的创新药物。本次案件涉及耐赋康所 依托的中国发明专利（专利号：ZL200980127272.5），目前仍处于有效保护期内，有效期至2029年5月。 本报讯 （记者金婉霞）近日，云顶新耀有限公司（以下简称"云顶新耀"）披露消息称，由该公司原研创新药耐赋康（布地 奈德肠溶胶囊）相关专利维权取得阶段性进展：广州知识产权法院已就案件作出诉前行为保全裁定，责令相关企业停止被诉行 为并停止产品挂网，裁定自作出之日起执行。 （编辑 郭之宸） 云顶新耀方面表示，公司将继续依法维护知识产权权益，推动创新疗法持续惠及患者。 ...

Core Viewpoint - Novo Nordisk (NVO.US) shares rose over 4% to $49.88 following the news that competitor Hims & Hers Health (HIMS.US) has withdrawn its plans to launch a low-cost generic weight loss drug due to regulatory and legal pressures, alleviating market concerns about the impact of cheaper alternatives on Novo Nordisk's core products [1] Group 1: Market Impact - The withdrawal of Hims & Hers Health's generic weight loss drug plan significantly eases concerns regarding the competitive threat to Novo Nordisk's GLP-1 drug market [1] - Novo Nordisk's stock repurchase plan has been announced, with a maximum buyback amount of 15 billion Danish kroner [1] Group 2: Legal Actions - Novo Nordisk has filed a lawsuit in Delaware against Hims, alleging that Hims' products, including its weight loss injection, are composite forms of semaglutide, thus infringing on its patents [1] - Novo Nordisk's statement highlights that Hims has engaged in promotional activities that mislead consumers and healthcare professionals regarding the clinical efficacy and safety of its unapproved drugs [1]

Core Viewpoint - The company has noted the approval of a generic version of its marketed product Budesonide Enteric-Coated Capsules (Nafacon) [1] Group 1 - The original product Nafacon is protected by patent ZL200980127272.5 in China, which is currently valid until May 7, 2029 [1] - The company reserves the right to take legal action against any infringement of the patent rights and commitments [1]

Core Viewpoint - The recent patent infringement lawsuit between Huadong Medicine and Zhaoli Pharmaceutical has concluded with Huadong Medicine's subsidiary losing the case, which involved over 1.11 billion yuan in claims, highlighting the competitive dynamics in the market for fermented Cordyceps sinensis products [1][7]. Group 1: Lawsuit Details - The lawsuit focused on the patent rights related to the invention of fermented Cordyceps sinensis powder and its formulations, with Huadong Medicine claiming infringement by Zhaoli Pharmaceutical's product, Bailin tablets [2][8]. - The Zhejiang High Court ruled that the accused products did not fall under the protection of the claimed patent, leading to the dismissal of all claims by Huadong Medicine and requiring them to pay over 590,000 yuan in court fees [3][10]. Group 2: Market Dynamics - The dispute reflects a significant market battle over the Bailin series, which has historically generated substantial revenue for Huadong Medicine, with sales peaking at 3.486 billion yuan in 2019 [4][11]. - Zhaoli Pharmaceutical has disrupted Huadong Medicine's market dominance by acquiring an 81% stake in Qinhai Zhu Feng Winter Worm Summer Grass Pharmaceutical Co., thus integrating Bailin tablets into its portfolio [5][12]. - Zhaoli Pharmaceutical's Bailin series has seen a 38.51% increase in sales revenue, aided by its inclusion in multiple national insurance and basic drug catalogs, indicating a rapid market penetration [5][12]. Group 3: Strategic Implications - The failed acquisition attempt by Huadong Medicine to gain control over Zhaoli Pharmaceutical in 2019 has intensified the competitive landscape, leading to a reliance on patent litigation as a defense strategy [6][12]. - Analysts suggest that the lawsuit's outcome is critical not only for the 1.11 billion yuan claim but also for Huadong Medicine's market influence in a sector valued at 30 billion yuan [6][12].

Core Insights - Jiangsu Overseas Talent Innovation and Entrepreneurship Alliance (Su Chuang Lian) is actively engaging with experts in the fields of biomedicine and new energy to enhance local industry development through talent and technology integration [1][3] Group 1: Expert Engagement - A delegation led by Su Chuang Lian's Secretary-General Wang Subiao visited the Danyang Provincial Sea Intelligence Base to conduct research and provide guidance [1] - The expert team visited companies such as Xinli Medical Technology Co., Ltd., Boda Intelligent Equipment (Zhenjiang) Co., Ltd., and Chery Technology (Jiangsu) Co., Ltd., focusing on topics like brain-computer interface and new energy battery equipment technology cooperation [3] Group 2: Industry Collaboration - The experts provided suggestions on industry-academia-research collaboration, integration of industrial chains, product export, and patent protection [3] - The team emphasized leveraging Su Chuang Lian's extensive network of technology talent resources to align with local industry development and enterprise needs [3] Group 3: Future Initiatives - Zhenjiang Science and Technology Association plans to act as a bridge to support the municipal government's innovation-driven industrial strategy [5] - The association will implement the "Science and Technology Innovation Pioneer" initiative to create platforms for cooperation and promote deep integration of technology and industry [5]

Core Viewpoint - The company is addressing concerns regarding the patent expiration of its flagship product, Xinhuosu, which is set to expire in 2031, and the potential impact of generic drugs entering the market [2] Group 1: Patent and Market Protection - The invention patent for Xinhuosu covers the formulation and preparation method, with a protection period from 2011 to 2031 [2] - The five-year new drug monitoring protection period has already expired, allowing other companies to develop and market related products [2] Group 2: Competitive Landscape - Suzhou Landing Biological has received approval for its recombinant human brain natriuretic peptide injection, indicating increased competition in the market [2] Group 3: Strategic Response - The company plans to enhance collaboration with commercial partners to expand the number of medical institutions covered by Xinhuosu, which currently includes nearly 7,000 institutions [2] - An investment of several million yuan is planned for exploratory research in evidence-based medicine for Xinhuosu, alongside ongoing academic promotion and production assurance efforts [2]

Core Insights - The article discusses the increasing risks faced by Chinese companies going overseas under the "Belt and Road" initiative, including contract disputes, intellectual property disputes, and labor disputes [1][2] - The successful launch of the 3A game "Black Myth: Wukong" highlights the importance of the "Changning Notarization" platform in protecting intellectual property through the "hash value notarization model" [2][4] - A recent patent dispute in the solar energy sector illustrates how a Chinese company overcame a patent infringement lawsuit from a U.S. energy firm, breaking the monopoly of international giants [4][5] Group 1: Intellectual Property Protection - The "Changning Notarization" platform allows real-time notarization of electronic data, protecting business secrets and providing evidence for potential infringement lawsuits [2][3] - The introduction of customized notarization service packages in Shanghai aims to meet the growing demand for public legal services, expanding into areas like intellectual property consultation and protection [2][3] Group 2: Legal Services for Overseas Expansion - The establishment of the "China Enterprises Going Global Headquarters Service Center" in Changning aims to provide legal support for local companies expanding internationally [3][4] - The successful invalidation of a U.S. energy company's patent by a Chinese firm demonstrates the effectiveness of legal services in supporting domestic companies against international patent challenges [5][6] Group 3: Innovative Service Models - The "accompanying overseas" service model allows notaries to assist companies in navigating legal requirements, ensuring compliance with foreign regulations [7] - The "housekeeper service" model streamlines the notarization process by allowing notaries to prepare necessary materials based on the company's needs, reducing the burden of evidence collection [7]

Core Viewpoint - The newly revised Shandong Province Patent Regulations aim to address challenges such as insufficient supply of high-value patents, low patent conversion efficiency, and difficulties in rights protection, emphasizing the need for improved patent quality and utilization [1][2]. Group 1: Legislative Background and Objectives - The revision of the patent regulations is necessary due to changes in national patent laws and the need to adapt to new situations in patent work, focusing on quality and application [1]. - The regulations are designed to establish a high-value patent cultivation mechanism, reward excellent patent projects, encourage employee inventions, and strengthen talent development [1]. Group 2: Key Provisions of the Regulations - The regulations consist of 33 articles and focus on enhancing the quality of patent applications, rewarding outstanding patent projects, and encouraging pre-application evaluations of patent value and market prospects [1]. - To promote patent conversion, the regulations require tracking and evaluation of patents formed from publicly funded research projects, with unimplemented patents after three years being included in a public implementation list [2]. Group 3: Strengthening Patent Protection and Management - The regulations establish a mechanism for coordination between patent administrative enforcement and judicial processes, enhancing collaboration among various legal entities [2]. - A public service system for patents will be established, including platforms for showcasing and trading patents, and a patent evaluation system to analyze patent rights and infringement risks before major projects [2]. Group 4: Implementation and Support - The implementation of the regulations is seen as a crucial step to address development challenges and align with national policies, with plans for supporting policies such as high-value patent cultivation centers and financial support for patent rights protection [2].

Core Viewpoint - The newly revised "Shandong Province Patent Regulations" aims to address challenges such as insufficient supply of high-value patents, low patent conversion efficiency, and difficulties in rights protection, emphasizing the need for improved patent quality and utilization [1][2]. Group 1: Legislative Background and Objectives - The revision of the patent regulations is prompted by changes in national patent laws and the need to adapt to new situations in patent work, focusing on enhancing patent quality and application [1]. - The regulations are designed with a "whole chain governance" approach to strengthen the legal framework for patent protection [1]. Group 2: Key Provisions of the Regulations - The regulations consist of 33 articles that do not follow traditional chapter divisions, focusing on promoting the cultivation of high-value patents and rewarding excellent patent projects [1]. - The regulations encourage the evaluation of patent value and market prospects before application, and provide incentives for employees who contribute significantly to the transformation of occupational scientific achievements [1][2]. Group 3: Implementation and Support Mechanisms - To facilitate patent conversion, the regulations mandate tracking and evaluation of patents formed from publicly funded research projects, with a provision for patents not implemented within three years to be included in a public implementation list [2]. - The regulations establish a mechanism for coordination between patent administrative enforcement and judicial processes, enhancing collaboration among various legal entities [2]. - A public service system for patents will be established, including platforms for showcasing and trading patents, and a patent evaluation system to analyze patent rights and infringement risks before major projects [2].

Core Viewpoint - Microchip Biotech's stock fell over 5% following the announcement of a patent invalidation decision by the National Intellectual Property Administration, declaring the patent related to its drug, Sidabamine, completely invalid [1][2]. Group 1: Patent Invalidation Impact - The invalidation decision regarding the patent for Sidabamine does not affect the overall patent protection system that the company has established around the drug, which includes multiple patents covering various aspects such as compound, crystal form, key processes, formulations, and indications [2][3]. - The invalidated patent pertains specifically to the indication for peripheral T-cell lymphoma (PTCL), but the company maintains that this does not undermine the validity of other patents protecting Sidabamine [2][3]. Group 2: Drug Approval and Market Position - Sidabamine has received approvals for three indications in China: PTCL in December 2014, breast cancer (BC) in November 2019, and diffuse large B-cell lymphoma (DLBCL) in April 2024, with PTCL and DLBCL being conditionally approved [3]. - The breast cancer indication has not yet been included in the national medical insurance catalog, and the market is competitive with several lower-priced alternatives already listed, resulting in a minor contribution to the company's revenue [3]. Group 3: Financial Performance - For the first half of 2025, Microchip Biotech reported a revenue of 407 million yuan, representing a year-on-year increase of 34.56%, and a net profit attributable to shareholders of 29.59 million yuan, up 172.16% year-on-year [3][4]. - The growth in revenue is attributed to increased sales of Sidabamine and Siglecatin [4].